










© Sleep Research Society 2019. Published by Oxford University Press on behalf of the Sleep 
Research Society. All rights reserved. For permissions, please e-mail 
journals.permissions@oup.com. 
Effect of continuous positive airway pressure on inflammatory, 
antioxidant, and depression biomarkers in women with obstructive 
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Study objectives. The effect of continuous positive airway pressure (CPAP) on 
mediators of cardiovascular disease and depression in women with obstructive sleep 
apnea (OSA) is unknown. We aimed to assess the effect of CPAP therapy on a variety 
of biomarkers of inflammation, antioxidant activity and depression in women with 
OSA. 
Methods. We conducted a multicenter, randomized controlled trial in 247 women 
diagnosed with moderate-to-severe OSA (apnea-hypopnea index [AHI]≥15). Women 
were randomized to CPAP (n=120) or conservative treatment (n=127) for 12 weeks. 
Changes in tumor necrosis factor α (TNFα), interleukin 6 (IL-6), C-reactive protein 
(CRP), intercellular adhesion molecule 1 (ICAM-1), catalase (CAT), superoxide 
dismutase (SOD), and brain-derived neurotrophic factor (BDNF) were assessed. 
Additional analyses were conducted in subgroups of clinical interest. 
Results. Women had a median (25th-75th percentiles) age of 58 (51-65) years, body 
mass index 33.5 (29.0-38.3) Kg/m2 and AHI 33.3 (22.8-49.3). No differences were 
found between groups in the baseline levels of the biomarkers.   
After 12 weeks of follow-up, there were no changes between groups in any of the 
biomarkers assessed. These results did not change when the analyses were restricted to 
sleepy women or to those with severe OSA. In women with CPAP use ≥5 hours/night, 
only TNFα levels decreased compared to the control group (-0.29±1.1 vs -0.06±0.53, 
intergroup difference -0.23 [95%CI -0.03 to -0.50]; p=0.043). 
Conclusions. Twelve weeks of CPAP therapy does not improve biomarkers of 
inflammation, antioxidant activity or depression compared to conservative treatment in 
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Statement of significance  
Obstructive sleep apnea (OSA) is associated with systemic inflammation and oxidative 
stress, however, the effect of continuous positive airway pressure (CPAP) therapy on 
inflammatory or antioxidant biomarkers has not yet been assessed in women. We have 
conducted the first randomized controlled trial to investigate the effect of CPAP on a 
wide variety of inflammation, antioxidant activity and depression biomarkers in female 
population. Compared with the control group, 12 weeks of CPAP therapy did not 
achieve any significant improvement in any of the biomarkers assessed. Only in women 
with CPAP use ≥5 hours/night, TNFα levels decreased compared to the control group. 
These results do not support the treatment of OSA based on an expectancy of 























Obstructive sleep apnea (OSA) has been recognized as a risk factor for hypertension, 
cardiovascular disease, quality of life (QoL) impairment and depression 
1–3
. OSA is 
characterized by recurrent upper airway obstruction episodes that provoke intrathoracic 
pressure surges, sleep fragmentation, and hypoxia-reoxygenation cycles, which trigger a 
variety of intermediate mechanisms that mediate these clinical outcomes 
1,4
. More 
specifically, intermittent hypoxia (IH) results in increased reactive oxygen species 
leading, to oxidative stress and systemic inflammation. Both these conditions have been 
well documented in patients with OSA, and they are also known to be mechanistic 
facilitators of cardiovascular diseases and other disorders such as depression 
1,5–7
. Thus, 
the study of these intermediate pathways may help us to understand the different clinical 
consequences of OSA, and they could be used as surrogate outcome measures in the 
cardiovascular and mood disorder fields.  
Several studies have analyzed the effect of continuous positive airway pressure therapy 
(CPAP) on a wide variety of biomarkers of oxidative stress and inflammation, but most 
of them either used an observational design or enrolled a relatively small sample 
8–12
. 
The few randomized-controlled trials (RCT) with larger sample sizes, however, are 
restricted to men or do not adequately analyze a possible gender effect, and none of 
them assessed biomarkers associated with mood disorders such as depression 
13–16
. 
Given that OSA differs between men and women in terms of prevalence, 
pathophysiology, severity, clinical presentation, and association with mood disorders 
17
, 
a differing response can be expected in the molecular signatures of OSA in both 
genders. In fact, some data suggest that oxidative stress may be more associated with 
























Our group has recently published the results of a RCT that investigated the effect of 12 
weeks of CPAP on different clinical outcomes in women with moderate-to-severe OSA 
19,20
. In the current study, we address the effect of CPAP on the levels of inflammatory, 
antioxidant activity, and depression biomarkers in this cohort of women with OSA.  
 
METHODS 
Design, settings and patients 
This multicenter, open-label, randomized-controlled trial of parallel groups with final 
blind evaluation, addressed the effect of 12 weeks of CPAP on a variety of clinical 
outcomes, including QoL, mood disorders, and BP in women with moderate-to-severe 
OSA (NCT02047071). The study design and population has previously been described 
in detail 
19,20
. Briefly, women between 18-75 years referred for OSA suspicion and 
diagnosed with moderate-to-severe OSA (apnea-hypopnea index [AHI] ≥15) in 19 
Spanish Sleep Units were eligible for the study. Women were excluded if they had 
respiratory failure, heart failure grade III-IV NYHA, unstable disorders, pregnancy, 
severe daytime sleepiness (Epworth sleepiness score [ESS]>18), prior diagnosis of OSA 
or CPAP treatment or central sleep apnea. The study was approved by the Ethics 
Committee of each participating center. All the participants provided informed signed 
consent.  
The current study includes those women in whom blood samples were obtained and 
available for analysis at baseline and after 12 weeks of follow-up.   
Procedures 






















Every woman underwent a home respiratory polygraphy with a device previously 
validated against polysomnography. Every sleep study was manually scored by skilled 
staff. All the studies included recording of the oro-nasal flow and pressure, respiratory 
movements, and oxyhemoglobin saturation (SaO2). Apnea was defined as complete 
cessation of oro-nasal flow for ≥10 seconds and was classified as either obstructive or 
central, based on the presence or absence of respiratory efforts. Hypopnea was defined 
as a 30-90% reduction in oro-nasal flow for ≥10 seconds followed by a ≥3% decrease in 
SaO2. The AHI was defined as the number of apnea plus hypopnea per hour of 
recording. A sleep study was considered valid if at least 4 hours of re ording and more 
than 3 hours of subjective sleep were reported. 
After OSA diagnosis, the women completed a standardized protocol that included 
general and anthropometric data, menopausal status, history of cardiovascular diseases, 
subjective sleep duration, subjective sleepiness measured by the Epworth Sleepiness 
Scale (ESS) 
21
, and clinical history related to OSA. 
 
Blood sampling 
After OSA diagnosis and prior to randomization, blood samples were collected after an 
overnight fast (between 07:00 and 09:00 hours). Tubes were centrifuged and 
plasma/serum samples were aliquoted and stored at −80°C. In this study, we assessed 
the following biomarkers of inflammation, antioxidant activity and depression: tumor 
necrosis factor α (TNFα), interleukin 6 (IL-6), C-reactive protein (CRP), intercellular 
adhesion molecule 1 (ICAM-1), catalase activity (CAT), superoxide dismutase activity 






















at the Instituto de Biomedicina de Sevilla (IBiS). Detailed data from these analyses are 
provided in the supplementary file and supplementary Table 1. 
 
Randomization and Intervention 
Women with an AHI ≥15 were randomized to either CPAP or conservative treatment by 
using a computer-generated list of random numbers in the coordinating center and 
stratified by center. The results were mailed in numbered, opaque, sealed envelopes.  
Women randomized to the conservative treatment group received dietary and sleep 
hygiene counseling, whereas those allocated to the treatment group received dietary and 
sleep hygiene counseling plus CPAP. The participants were advised not to change their 
cardiovascular medication throughout the follow-up, unless dictated by clinical needs. 
For those women randomized to CPAP therapy, the optimal pressure was titrated on a 
second night, using an auto CPAP device, according to a previous validation by the 
Spanish Sleep Network 
22
. The optimal pressure was determined in a centralized 
manner, by two blinded expert researchers, based on the visual evaluation of the raw 
data recording from the night study, with no significant leaks (less than 0.40 L/s). This 
fixed pressure was maintained throughout the study. 
 
Study endpoints 
The endpoint of the present study was the changes in the biomarkers of inflammation, 
antioxidant activity and depression at 12 weeks compared to baseline, in the CPAP 
























The initial sample size was calculated for the primary endpoint of the original study 
(QoL), but also for enough power to analyze other secondary endpoints. In the current 
study, the sample size consists of 247 women (120 allocated to CPAP and 127 to 
conservative treatment). This sample size would enable us to detect, with an α error of 
0.05 and a power of 90%, a change of at least 4 ng/mL with an SD of 7 ng/mL in BDNF 
levels between groups (at least 70 participants would be needed in each group) 
23
, as 
well as to detect a change of at least 1 mg/L with an SD of 2 mg/L in CRP levels 





Results are expressed as mean (SD) or median (25th-75th percentiles) for continuous 
variables and number of patients (%) for categorical variables. Baseline continuous 
variables were compared using the Mann-Whitney test, and categorical variables were 
compared using Chi-square or Fisher exact tests, as appropriate. 
The inter-group comparison of the changes in the biomarker levels were assessed by 
analysis of covariance with adjustments for baseline values and age. The analyses were 
performed on an intention-to-treat basis. An additional per-protocol analysis was 
conducted, including in the CPAP group only those patients who used the device for at 
least 5 hours/night in average.  
We conducted sensitivity analyses to investigate the effect of CPAP therapy on specific 
subgroups of clinical interest, such as those with severe OSA (AHI≥30) and those with 






















Spearman correlation and scatterplots were used to investigate whether there were any 
relationships between the change (final-baseline) in biomarker levels and CPAP 
adherence measured by the hours of CPAP use, or the change in ESS, systolic and 
diastolic BP. 
Two-tailed p-values of <0.05 were considered significant. IBM SPSS 23.0 statistical 
package (IBM, Armonk, NY, USA) was used for data processing and analysis. 
 
RESULTS 
Of the 571 women initially assessed, 307 were randomized in the original study, and 
247 (120 allocated to CPAP and 127 to conservative treatment) had blood samples 
available at baseline and 12 weeks, and were finally included in the current study 
(Figure 1). The reason for the absence of blood samples in 60 women is that some 
centers did not have the means to centrifuge the blood samples and store them at -80°C, 
so they did not participate in this secondary analysis. There were no differences in terms 
of age, BMI, ESS, menopausal status, AHI, T90, ODI3, or minimum SaO2 (p>0.05 for 
all comparisons) between the group of 60 women without blood samples and the group 
of 247 with blood samples. 
Women had a median (25th-75th percentiles) age of 58 (51-65) years (77.3% were 
postmenopausal), body mass index (BMI) 33.5 (29.0-38.3) Kg/m2 (71.2% had a 
BMI≥30), waist-to-hip ratio 0.90 (0.86-0.94), ESS 10 (6-13) and AHI 33.3 (22.8-49.3). 
The CPAP and control groups were comparable, except for age; women in the CPAP 
group were older than those in the control group (Table 1). The baseline levels of the 
different biomarkers were similar between groups. No significant change in weight was 






















In the treated group, the median CPAP pressure was 10 (8-12) cmH2O, the average 
residual AHI after titration was 2.0 (0.7-4.1), the mean (SD) adherence to the device 
after 12 weeks was 5.0 (2.2) hours/night, and 76 women (63.3%) had adherence of at 
least 5 hours or higher.  
 
Intention-to-treat analysis 
In both the CPAP and control groups, there was a significant improvement in TNFα 
levels from baseline to 12 weeks. CRP levels also decreased in the CPAP group, but not 
in the control group (Table 2). However, there was no significant change in the levels 
of the inflammatory (IL-6, CRP, TNFα, ICAM-1), antioxidant activity (CAT, SOD) and 
depression (BDNF) biomarkers between the CPAP and control groups at the end of the 
follow-up (Table 2). 
 
Per-protocol analysis 
After 12 weeks of follow-up, there was no significant change in the levels of the IL-6, 
CRP, ICAM-1, CAT, SOD, and BDNF between those women with CPAP use ≥5 
hours/night and the control group (Table 3). However, a significant improvement was 
observed in the TNFα levels in the CPAP≥5 hours/night group, compared to the control 
group (-0.29±1.1 vs -0.06±0.53, non-adjusted intergroup difference -0.23 [95%CI -0.03 

























In the subgroup of women with an AHI≥30, we did not find any changes in the 
biomarker levels between groups, at the end of the follow-up, compared to baseline 
(Table 3). Similarly, no changes were observed in the subgroup of women with an 
ESS>10 (Table 3). 
No correlations were found between the changes in the biomarkers at 12 weeks 
compared to baseline and the changes during this period in the ESS score, systolic BP 
and diastolic BP (supplementary Table 2), or between the changes in the biomarkers 
and the average hours of CPAP use (supplementary Table 3). 
 
DISCUSSION 
To the best of our knowledge, this is the first RCT to investigate the effect of CPAP on 
a wide range of inflammatory and antioxidant activity biomarkers in a population 
specifically composed of OSA women, as well being the first to analyze markers of 
depression in OSA patients. Our results do not support any effect of CPAP therapy on 
biomarkers of inflammation, antioxidant activity or depression in women with 
moderate-to-severe OSA, except in the TNFα levels of those who had above-average 
CPAP adherence.  
Although repetitive cycles of IH have been associated with a rise in different markers of 
inflammation and oxidative stress in OSA patients, few studies have specifically 
analyzed this effect in women 
24,25
. Svensson et al studied 398 women from the general 
population and found that CRP and IL6 levels were increased in women with OSA, 
defined as an AHI≥15, compared to those without OSA (1.9 vs 1.3 mg/L, p=0.003; and 
1.0 vs 0.8 ng/L, p=0.04, respectively), whereas TNF levels were similar in both groups 
(2.0 vs 2.0 pg/mL, p=0.7) 
26






















oxidative stress in elderly women, but not in elderly men 
18
. A study in a population-
based cohort of 295 midlife women showed that lower sleep efficiency was associated 
with higher circulating levels of IL-6 
27
. Given that CPAP has consistently been shown 
to prevent IH associated with OSA, there is a pathophysiological rationale to expect a 
beneficial effect from CPAP therapy on these biomarkers of inflammation and oxidative 
stress. 
OSA is a risk factor for mood disorders, particularly depression 
3
. There are gender 
differences in this association, with a prevalence of depression of 35% in OSA women, 
compared to 12-25% in men 
28,29
. To our knowledge, no study has previously 
investigated the possible effect of OSA therapy on biomarkers of depression, but since 
there is now evidence to suggest that inflammation and oxidative stress may play a role 
in the pathophysiology of major depressive disorders 
5–7
, and since the levels of some 
markers such as BDNF have been reported to decrease in patients with depression and 
increase with antidepressant therapy 
23
, there would also be a rationale for expecting an 
improvement in these biomarkers in OSA women. 
Our results, however, do not support these hypotheses as we did not find any 
improvement in different biomarkers of inflammation, antioxidant activity or depression 
in our sample. Although observational studies and some small RCTs have reported a 
controversial effect of CPAP 
8–10,30,31
, our results concur with those of recent larger 
RCTs which did not observe any beneficial effect of CPAP therapy on a wide range of 
biomarkers, including IL-6, IL-8, IL-10, CRP, TNFα, F2-isoprostanes, and 
myeloperoxidase 
13–16
. These studies predominantly featured men, however, or they 
failed to investigate any potentially different outcome in women. 
The lack of effect of CPAP on diverse biomarkers observed in our study cannot be 






















shown, using this same cohort, that 12 weeks of CPAP therapy significantly improved 
different aspects of QoL, daytime sleepiness, mood state and depression symptoms, as 
well as BP measurements, compared to conservative treatment 
19,20
, so other reasons 
should be sought to explain our results.    
Given that there is a relationship between certain cytokines and excessive daytime 
sleepiness (EDS) 
32,33
, it has been argued that the effect of CPAP may be reduced in 
non-sleepy OSA patients 
16
. The median ESS in our sample was 10, but when we 
specifically studied a subgroup of women with EDS (ESS>10), the results did not 
change. Some researchers have noted, however, that inflammation may be associated 
with objective rather than with subjective sleepiness 
34
. 
Other studies have attributed their negative results to the enrolment of non-severe OSA 
patients. Paz y Mar et al argued that in their trial, the mean AHI of 20/h and 2% sleep 
time <90% oxygen saturation (T90) may have not been sufficient to result in oxidative 
stress up-regulation 
15
. In our study, the median AHI was 33.3/h, which is in the range 
of severe OSA, and the median T90% was 8.4% (i.e., four times higher than in the Paz 
y Mar study). Furthermore, even when we analyzed a subgroup of women with an 
AHI≥30, no differences were observed between groups. 
Another possibility is that the lack of effect of CPAP therapy may have been due to the 
relatively short duration of treatment. In this respect, however, 12 weeks of CPAP were 
enough to detect an improvement in clinical outcomes in this same cohort, as previously 
stated. Although it cannot be ruled out that a longer treatment period may have achieved 
discernible changes, another trial showed no improvement in inflammatory biomarkers 
























Other possibilities cannot be excluded. For instance, many of the biomarkers assessed in 
this study are also associated with obesity, which was present in 71.2% of our sample, 
and did not change during the follow-up. If these biomarkers were more closely related 
to obesity than to OSA, CPAP would play only a minor role in improving their levels 
35,36
. Although we have used some of the most widely studied biomarkers related to 
OSA, we cannot confirm that they are the most accurate surrogates for measuring the 
CPAP response to inflammation and oxidative stress associated with OSA 
11,12,24
. 
Finally, it is unclear whether OSA is associated with higher cardiovascular risk in the 
elderly 
37
, although our sample had a median age of 58 years and therefore cannot be 
considered elderly. Nevertheless, to account for this possibility, and given that there 
were baseline age differences between groups, we specifically analyzed the subgroup of 
women under 58 years, but the results did not change (data not shown). 
Adherence has been highlighted as a key reason to explain the negative effect of CPAP 
on cardiovascular outcomes in recent RCTs 
38,39
. This was not the case in our RCT. The 
average adherence in our study was 5.0 (2.2) hours/night, which can be considered 
adequate. Furthermore, when we selected a subgroup of women with adherence above 
the average, the results did not change, except for TNFα, which significantly decreased 
compared to conservative treatment. Whether this finding means that this biomarker is 
more sensitive to the effect of CPAP or better reflects the inflammatory process 
associated with OSA should be addressed in future studies. 
Our study has limitations. First, OSA was diagnosed by means of a respiratory 
polygraphy, rather than by a conventional polysomnography, but it seems unlikely that 
the diagnostic method influenced the final findings. Second, sleepiness was not 
objectively assessed, and since inflammation seems to be associated with objective 
sleepiness 
34






















may have precluded any beneficial effect of CPAP on, at least, some of the biomarkers. 
Third, although we previously found an improvement in QoL, mood state and 
depression in this cohort 
19
, only 20.2% of the women could be defined as having 
depression, according to the Hospital Anxiety and Depression questionnaire score, so 
the small proportion of depressive women may have prevented us from detecting a 
beneficial effect in some markers, such as the BDNF. Finally, the lack of observed 
effect may be due to the fact that biomarker measures at baseline were within the 
normal range. Unfortunately, we do not have a control group of non-OSA women to 
compare. However, the CRP and IL6 measures for women in our cohort were higher 
than those observed in women with OSA in Svensson’s study (3.6 vs 1.9 mg/L, and 2.7 
vs 1.0 pg/mL, respectively), and more than three times higher compared to non-OSA 
women (3.6 vs 1.3 mg/L, and 2.7 vs 0.8 pg/mL, respectively). Thus, at least for these 
biomarkers, the baseline levels were above normal values and, therefore, a “floor effect” 
would not explain our negative results. Nevertheless, in order to account for this 
limitation, we analyzed different subgroups of clinical interest in which these CV 
biomarkers would be expected to be increased, such as women with more severe OSA 
and women with excessive daytime somnolence. Furthermore, we have run an 
exploratory analysis to investigate the effects of CPAP on those women who were in the 
upper tertiles of each biomarker at baseline, so that only those with the highest levels 
were analyzed. This analysis showed no differences between the CPAP and control 
groups in any of the biomarkers assessed (data not shown), which supports the main 
findings of our study.  
 
In conclusion, 12 weeks of CPAP therapy did not change the circulating levels of a 






















with moderate-to-severe OSA, compared to a non-treated control group. Given that 
CPAP showed a beneficial clinical effect in this same cohort, it is possible that other 
intermediate pathways not assessed in this study play a greater role in the outcomes of 
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AHI: apnea-hypopnea index 
BDNF: brain-derived neurotrophic factor 
BMI: body mass index 
BP: blood pressure 
CAT: catalase 
CPAP: continuous positive airway pressure 
CRP: C-reactive protein 
EDS: excessive daytime sleepiness 
ESS: Epworth sleepiness score 
ICAM-1: intercellular adhesion molecule 1  
IL-6: interleukin 6 
IH: intermittent hypoxia 
OSA: obstructive sleep apnea  
QoL: quality of life  
RCT: randomized-controlled trials 
SaO2: oxyhemoglobin saturation  
SOD: superoxide dismutase 
TNFα: tumor necrosis factor α 
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Table 1. Baseline characteristics of the sample. 
 
Variables Whole group  
(n= 247) 





Age (years) 58.0 (51.0 – 65.0) 56.0 (50.0 – 63.0) 60.0 (53.0 – 67.0) 0.006 
BMI (kg/m
2
) 33.5 (29.0 – 38.3) 33.5 (29.7 – 39.4) 33.5 (28.8 – 37.1) 0.183 
Neck circumference (cm) 37.0 (35.0 – 40.0) 38.0 (35.0 – 40.0) 37.0 (35.0 – 40.0) 0.174 
Waist-to-hip ratio 0.90 (0.86 – 0.94) 0.90 (0.86 – 0.95) 0.90 (0.85 – 0.94) 0.150 
Post-menopausal  191 (77.3%) 95 (74.8%) 96 (80.0%) 0.364 
Physical activity  
(< 30 min/day) 
122 (49.4%) 65 (51.1% ) 57 (47.5% ) 0.407 
Sleep duration (hours/day) 7.5 (6.0 – 8.3) 7.5 (6.0 – 8.3) 7.0 (6.0 – 8.3) 0.466 






















Diastolic BP (mm Hg) 80.0 (72.5 – 90.0) 80.0 (72.5 – 89.0) 80.0 (70.0 – 90.0) 0.723 
Prior cardiovascular Events  20 (8.1%) 11 (8.7%) 9 (8.1%) 0.935 
Apnea-Hypopnea index 33.3 (22.8 – 49.3) 31.4 (20.3 – 47.2) 35.9 (24.2 – 50.1) 0.168 
Oxygen desaturation index 
(3%) 
32.9 (22.1 – 49.7) 30.4 (21.1 – 50.0) 34.6 (23.3 – 49.7) 0.381 
Minimum SaO2  77.0 (70.0 – 83.0) 78.0 (72.0 – 83.0) 77.0 (70.0 – 83.0) 0.662 
T90% 8.4 (2.3 – 29.1) 10.0 (2.3 – 29.1) 7.8 (2.4 – 29.1) 0.887 
Epworth score 10.0 (6.0 – 13.0) 10.0 (6.0 – 13.0) 10.0 (7.0 – 13.0) 0.229 
BDNF (ng/mL) 33.257 (25.416- 40.202) 33.286 (241.69-42.214) 33.229 (25.556-39.147)   0.640 
IL6 (pg/mL) 2.79 (1.76 – 4.31) 2.79 (1.77 – 4.31) 2.77 (1.75 – 4.34) 0.854 
TNFα (pg/mL) 0.90 (0.69 – 1.21)  0.91 (0.69 – 1.25) 0.89 (0.71 – 1.15) 0.984 






















ICAM-1 (pg/mL) 254.0 (197.0 – 325.0) 265.0 (201.0 – 348.0) 251.0 (190.3 – 300.3) 0.091 
CAT (nmol/min/mL) 31.2 (24.1 – 40.0) 31.8 (25.4 – 41.9) 30.9 (23.2 – 37.4)  0.131 
SOD (U/ml) 0.25 (0.06 – 0.61) 0.23 (0.03 – 0.60)  0.26 (0.07 – 0.62)  0.584 
 
Results are expressed as mean ±SD or median (25th-75th percentiles), or Nº (%) 
BMI: body mass index. BP: blood pressure. T90%: % night-time spent with oxygen saturation below 90%. BDNF: brain-derived neurotrophic 
factor. IL-6: interleukin 6. TNFα: tumor necrosis factor α. CRP: C-reactive protein. ICAM-1: intercellular adhesion molecule 1. CAT: catalase. 





























Table 2. Effect of CPAP treatment on biomarkers of depression, inflammation and oxidative stress. Results of the intention-to-treat analysis. 
Biomarkers CPAP group Control group  Non-adjusted Inter-
group differences 
(95%CI) *, ** 
p-
value 









BDNF 32.09 ± 11.48 31.73 ± 14.10 0.35 ± 13.35 0.771 32.55 ± 11.00 32.34 ± 13.67 0.20 ± 13.37 0.862 0.14 (-3.21 to 3.51) 0.931 
IL6 3.5 ± 2.6 3.6 ± 2.8 -0.15 ± 2.5 0.500 3.6 ± 2.5 3.8 ± 5.0 -0.23 ± 5.2 0.622 0.07 (-0.95 to 1.1) 0.394 
TNFα 0.95 ± 0.36 1.1 ± 0.78 -0.14 ± 0.70 0.032 1.06 ± 1.46 1.35 ± 1.72 -0.29 ± 1.1 0.004 0.15 (-0.08 to 0.38) 0.198 
CRP 3.58 ± 2.09 3.86 ± 2.18 -0.28 ± 1.38 0.033 3.69 ± 1.99 3.87 ± 2.12 -0.18 ± 1.39 0.155 -0.10 (-0.46 to 0.25) 0.563 
ICAM-1 259.2 ± 96.5 264.1 ± 114.8 -4.9 ± 87.4 0.540 280.4 ± 109.7 290.4 ± 125.1 -10.0 ± 69.4 0.106 5.1 (-14.6 to 24.8) 0.610 
CAT 33.3 ± 17.6 32.6 ± 16.1 0.70 ± 18.4 0.680 34.8 ± 18.0 35.8 ± 17.3 -0.99 ± 20.0 0.577 1.7 (-3.2 to 6.6) 0.492 























* The inter-group differences are expressed as the effect of continuous positive airway pressure treatment versus conservative treatment, at the 
end of the follow-up compared with baseline. 
** Further adjustment for baseline values and age did not change the results. 
 
CPAP: continuous positive airway pressure. BDNF: brain-derived neurotrophic factor. IL-6: interleukin 6. TNFα: tumour necrosis factor α. CRP: 




























Table 3. Effect of continuous positive airway pressure therapy on biomarkers of depression, inflammation and oxidative stress in the subgroups 
of women with good adherence to CPAP (defined as an average use of at least 5 hours/night), excessive daytime sleepiness (defined as an 
Epworth score >10), and severe OSA (defined as an AHI≥30).  
 
Biomarkers CPAP group Control group  Non-adjusted Inter-group 







CPAP use ≥5 hours/night n=75 n=127   
BDNF 1.564 ± 14.840 0.208 ± 13.377 1.356 (-2.652 to 5.365) 0.845 
IL6 -0.49 ± 2.1 -0.23 ± 5.2 0.27 (1.49 to 0.96) 0.392 
TNFα -0.29 ± 1.1 -0.06 ± 0.53 -0.23 (-0.03 to -0.50) 0.043 
CRP -0.337 ± 1.312 -0.181 ± 1.394 0.155 (0.562 to 0.250) 0.450 






















CAT -2.5 ± 16.7 -0.99 ± 20.0 -1.5 (-6.9 to 3.9) 0.582 
SOD 0.03 ±0.26 0.10 ± 0.51 -0.07 (-0.2 to 0.05) 0.255 
Epworth >10 n=57 n=54   
BDNF 1.104 ± 13.170 -1.368 ± 14.738 2.473 (-2.777 to 7.723) 0.353 
IL6 0.15 ± 3.0 0.61 ± 2.4 0.46 (1.49 to 0.57) 0.448 
TNFα -0.18 ± 0.8 -0.29 ± 1.3 0.12 (-0.29 to 0.53) 0.397 
CRP -0.170 ± 1.383 -0.070 ± 1.221 0.100 (0.609 to 0.409) 0.454 
ICAM-1 -8.5 ± 87.7 -5.4 ± 67.2 3.1 (32.5 to 26.3) 0.500 
CAT 0.85 ± 21.2 -3.9 ± 15.8 4.8 (-2.3 to 11.9) 0.181 
SOD 0.01 ± 0.25 0.15 ± 0.71 -0.15 (-0.35 to 0.05) 0.154 
AHI≥ 30 n=72 n=77   
BDNF 2.666 ± 13.023 2.590 ± 13.367 0.076 (-4.368 to 4.521) 0.973 
IL6 -0.03 ± 3.0 0.01 ± 6.6 -0.04 (-1.7 to 1.6) 0.960 
TNFα -0.16 ± 0.8 -0.40 ± 1.1 0.24 (-0.07 to 0.55) 0.135 






















ICAM-1 1.4 ± 99.8 -9.3 ± 75.6 10.6 (-19.2 to 40.5) 0.482 
CAT -0.1 ± 16.0 1.11 ± 19.7 -1.2 (-7.3 to 4.9) 0.702 
SOD 0.02 ± 0.28 0.07 ± 0.37 -0.05 (-0.16 to 0.06) 0.374 
 
* The inter-group differences are expressed as the effect of continuous positive airway pressure treatment versus conservative treatment, at the 
end of the follow-up compared with baseline. 
** Further adjustment for baseline values did not change the results. 
 
CPAP: continuous positive airway pressure. AHI: apnea-hypopnea index. BDNF: brain-derived neurotrophic factor. IL-6: interleukin 6. TNFα: 
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